A systematic and objective approach to the selection of nanomedicines and nanosimilars for clinical use
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: FLüHMANN, Beat (., Zürich, Switzerland)
- Co-author(s): Beat Flühmann: Regulatory Science, Vifor Pharma Ltd, Zürich, Switzerland
Stefan Mühlebach: Regulatory Science, Vifor Pharma Ltd, Zürich, Switzerland
In recent years nanomedicines are becoming increasingly available. Up to 23 nanomedicines are approved, and approximately 50 are in clinical development. First followon medicinal products (nano similars) have entered the European market by applying the generic approval pathway, neglecting their nano colloidal properties. After.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.